A phase-I open-label study of the absorption, metabolism, and excretion of (14C)-ramelteon (TAK-375) following a single oral dose in healthy male subjects

被引：0
|
作者：
Hibberd, M
Stevenson, SJ
机构：
[1] Takeda Europe Res & Dev Ctr Ltd, London, England
[2] Covance Clin Res Unit Ltd, Leeds, W Yorkshire, England
来源：
SLEEP | 2004年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
121
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [1] Study of the absorption, metabolism, and excretion of (14C)-ramelteon (TAK-375).
    Stevenson, S
    Cornelissen, K
    Clarke, E
    Hibberd, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P22 - P22
  • [2] A phase I study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects
    Amakye, DD
    Hibberd, M
    Stevenson, SJ
    SLEEP, 2004, 27 : 54 - 54
  • [3] Study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects.
    Stevenson, S
    Bryson, S
    Amakye, D
    Hibberd, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P22 - P22
  • [4] Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An Open-Label, Phase I, Single-Dose Study in Healthy Men
    Scheers, Ellen
    Leclercq, Laurent
    de Jong, Jan
    Bode, Nini
    Bockx, Marc
    Laenen, Aline
    Cuyckens, Filip
    Skee, Donna
    Murphy, Joe
    Sukbuntherng, Juthamas
    Mannens, Geert
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (02) : 289 - 297
  • [5] A phase I, single-center, open-label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [14C] encorafenib in healthy male subjects
    Wollenberg, Lance
    Hahn, Erik
    Williams, Jason
    Litwiler, Kevin
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2023, 11 (05):
  • [6] A PHASE I, OPEN-LABEL STUDY OF THE ABSORPTION, METABOLISM, AND EXCRETION OF [14C]-SOTORASIB (AMG 510) IN HEALTHY MALE SUBJECTS.
    Vuu, I.
    Hutton, S.
    Purkis, J.
    Mather, O.
    Dutta, S.
    Houk, B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S49 - S50
  • [7] Absorption, metabolism, and excretion of oral [14C] radiolabeled donafenib: an open-label, phase I, single-dose study in humans
    Ma, Sheng
    Yi, Ling
    Bian, Yicong
    Lv, Binhua
    Zhang, Cong
    Li, Chengwei
    Zhang, Hua
    Miao, Liyan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2025, 95 (01)
  • [8] Absorption, Distribution, and Excretion of the Investigational Agent Orteronel (TAK-700) in Healthy Male Subjects: A Phase I, Open-Label, Single-Dose Study
    Suri, Ajit
    Pusalkar, Sandeepraj
    Li, Yuexian
    Prakash, Shimoga
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2016, 5 (03): : 180 - 187
  • [9] A PHASE ONE OPEN-LABEL SINGLE-RADIOLABELED DOSE STUDY TO INVESTIGATE THE ABSORPTION, METABOLISM, AND EXCRETION OF [14C]PD-0332991 IN HEALTHY MALE VOLUNTEERS
    Loi, Cho-Ming
    Vaz, Alfin
    Hoffman, Justin
    O'Gorman, Melissa
    Kirkovsky, Leonid
    Wang, Diane
    Dalvie, Deepak
    DRUG METABOLISM REVIEWS, 2015, 47 : 199 - 200
  • [10] Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study
    Nicholas Siebers
    Melissa Palmer
    Debra G. Silberg
    Lee Jennings
    Caleb Bliss
    Patrick T. Martin
    European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43 : 91 - 101
12345